TipRanks
Advertisement
Advertisement

NPCE Stock Latest News

NeuroPace initiated with an Overweight at KeyBanc
The FlyNeuroPace initiated with an Overweight at KeyBanc
20d ago
NPCE
NeuroPace initiated with an Overweight at KeyBanc
PremiumThe Fly
NeuroPace initiated with an Overweight at KeyBanc
20d ago
NPCE
Neuropace Earnings Call Shows Strong Growth Amid FDA Risk
PremiumCompany Announcements
Neuropace Earnings Call Shows Strong Growth Amid FDA Risk
1M ago
NPCE
NeuroPace reports Q2 EPS (18c), consensus (20c)
PremiumThe Fly
NeuroPace reports Q2 EPS (18c), consensus (20c)
2M ago
NPCE
NeuroPace raises FY26 revenue view to $99.5M-$101.5M from $99M-$101M
PremiumThe Fly
NeuroPace raises FY26 revenue view to $99.5M-$101.5M from $99M-$101M
2M ago
NPCE
NeuroPace: FDA seeks additional clinical evidence from NAUTILUS trial
PremiumThe FlyNeuroPace: FDA seeks additional clinical evidence from NAUTILUS trial
2M ago
NPCE
NeuroPace faces FDA setback on epilepsy label expansion
Premium
Company Announcements
NeuroPace faces FDA setback on epilepsy label expansion
2M ago
8K
NPCE
NeuroPace initiated with an Outperform at Mizuho
Premium
The Fly
NeuroPace initiated with an Outperform at Mizuho
3M ago
NPCE
NeuroPace Shareholders Approve Directors and Auditor at Meeting
PremiumCompany Announcements
NeuroPace Shareholders Approve Directors and Auditor at Meeting
4M ago
8K
NPCE
NeuroPace announces FDA approval of ECoG Assistant
PremiumThe Fly
NeuroPace announces FDA approval of ECoG Assistant
4M ago
NPCE
NeuroPace price target raised to $20 from $19 at H.C. Wainwright
PremiumThe Fly
NeuroPace price target raised to $20 from $19 at H.C. Wainwright
5M ago
NPCE
Neuropace Warns Cybersecurity Threats to Intracranial EEG Data Could Hit Operations, Reputation and Growth
PremiumCompany Announcements
Neuropace Warns Cybersecurity Threats to Intracranial EEG Data Could Hit Operations, Reputation and Growth
5M ago
NPCE
NeuroPace Earnings Call Highlights RNS Growth Momentum
PremiumCompany AnnouncementsNeuroPace Earnings Call Highlights RNS Growth Momentum
5M ago
NPCE
NeuroPace: Buy Rating Reiterated on Raised Guidance, Differentiated RNS Platform, and Attractive $20 Price Target Versus High-Growth Med-Tech Peers
Premium
Ratings
NeuroPace: Buy Rating Reiterated on Raised Guidance, Differentiated RNS Platform, and Attractive $20 Price Target Versus High-Growth Med-Tech Peers
5M ago
NPCE
NeuroPace reports Q1 EPS (20c), consensus (23c)
Premium
The Fly
NeuroPace reports Q1 EPS (20c), consensus (23c)
5M ago
NPCE
NeuroPace raises FY26 revenue view to $99M-$101M from $98M-$100M
PremiumThe Fly
NeuroPace raises FY26 revenue view to $99M-$101M from $98M-$100M
5M ago
NPCE
NeuroPace announces publication of 3-year results from RNS System PAS
PremiumThe Fly
NeuroPace announces publication of 3-year results from RNS System PAS
5M ago
NPCE
NeuroPace Earnings Call Highlights Growth And AI Push
PremiumCompany Announcements
NeuroPace Earnings Call Highlights Growth And AI Push
6M ago
NPCE
NeuroPace assumed with an Overweight at Wells Fargo
PremiumThe Fly
NeuroPace assumed with an Overweight at Wells Fargo
7M ago
NPCE
NeuroPace: Strong 2025 Execution, Reimbursement Tailwinds, and Label Expansion Upside Support Reiterated Buy and $19 Target
PremiumRatingsNeuroPace: Strong 2025 Execution, Reimbursement Tailwinds, and Label Expansion Upside Support Reiterated Buy and $19 Target
7M ago
NPCE
Regulatory Shutdowns Threaten Neuropace’s FDA Approvals and Capital Market Access
Premium
Company Announcements
Regulatory Shutdowns Threaten Neuropace’s FDA Approvals and Capital Market Access
7M ago
NPCE
NeuroPace reports Q4 EPS (8c), consensus (17c)
Premium
The Fly
NeuroPace reports Q4 EPS (8c), consensus (17c)
7M ago
NPCE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >